BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 14766261)

  • 1. The treatment of uterine leiomyosarcoma. Results from a 10-year experience (1990-1999) at the Massachusetts General Hospital.
    Dinh TA; Oliva EA; Fuller AF; Lee H; Goodman A
    Gynecol Oncol; 2004 Feb; 92(2):648-52. PubMed ID: 14766261
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Optimal management of uterine leiomyosarcoma.
    O'Cearbhaill R; Hensley ML
    Expert Rev Anticancer Ther; 2010 Feb; 10(2):153-69. PubMed ID: 20131992
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of uterine leiomyosarcoma.
    Berchuck A; Rubin SC; Hoskins WJ; Saigo PE; Pierce VK; Lewis JL
    Obstet Gynecol; 1988 Jun; 71(6 Pt 1):845-50. PubMed ID: 2453004
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Malignant mixed Müllerian tumors of the uterus: analysis of patterns of failure, prognostic factors, and treatment outcome.
    Callister M; Ramondetta LM; Jhingran A; Burke TW; Eifel PJ
    Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):786-96. PubMed ID: 14967435
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Secondary cytoreduction in the management of recurrent uterine leiomyosarcoma.
    Giuntoli RL; Garrett-Mayer E; Bristow RE; Gostout BS
    Gynecol Oncol; 2007 Jul; 106(1):82-8. PubMed ID: 17434579
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating prognostic parameters in women with uterine leiomyosarcoma. A clinicopathologic study.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    J Reprod Med; 2003 Feb; 48(2):95-100. PubMed ID: 12621792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic factors and impact of adjuvant chemotherapy for uterine leiomyosarcoma.
    Wu TI; Chang TC; Hsueh S; Hsu KH; Chou HH; Huang HJ; Lai CH
    Gynecol Oncol; 2006 Jan; 100(1):166-72. PubMed ID: 16182349
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Leiomyosarcoma of the inferior vena cava: prognosis and comparison with leiomyosarcoma of other anatomic sites.
    Hines OJ; Nelson S; Quinones-Baldrich WJ; Eilber FR
    Cancer; 1999 Mar; 85(5):1077-83. PubMed ID: 10091791
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Sarcoma of the prostate: a single institutional review.
    Janet NL; May AW; Akins RS
    Am J Clin Oncol; 2009 Feb; 32(1):27-9. PubMed ID: 19194120
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of treatment failures in patients with early-stage uterine leiomyosarcoma.
    Gadducci A; Fabrini MG; Bonuccelli A; Moda S; Fanucchi A; Laddaga M; Facchini V
    Anticancer Res; 1995; 15(2):485-8. PubMed ID: 7763027
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical outcome and prognostic factors in 100 cases of uterine sarcoma: experience in Helsinki University Central Hospital 1990-2001.
    Koivisto-Korander R; Butzow R; Koivisto AM; Leminen A
    Gynecol Oncol; 2008 Oct; 111(1):74-81. PubMed ID: 18657852
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Uterine leiomyosarcoma. Nine case reports, review of the literature].
    Razafintsalama T; Leveque J; Le Gall F; Paumier V; Pangui E; Kerisit J; Grall JY
    J Gynecol Obstet Biol Reprod (Paris); 1997; 26(3):256-62. PubMed ID: 9265046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogen and progesterone receptor expression in patients with uterine leiomyosarcoma and correlation with different clinicopathological parameters.
    Bodner K; Bodner-Adler B; Kimberger O; Czerwenka K; Leodolter S; Mayerhofer K
    Anticancer Res; 2003; 23(1B):729-32. PubMed ID: 12680175
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Metastatic lung tumor from uterine leiomyosarcoma].
    Nishida T; Shoji S; Itoh T; Minami H; Akizuki K; Ozuno I; Kageyama H; Ozaki I; Yamamoto K; Yamamoto A; Nishiyama N
    Kyobu Geka; 2006 Dec; 59(13):1191-6. PubMed ID: 17163213
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Improved survival in surgical stage I patients with uterine papillary serous carcinoma (UPSC) treated with adjuvant platinum-based chemotherapy.
    Kelly MG; O'malley DM; Hui P; McAlpine J; Yu H; Rutherford TJ; Azodi M; Schwartz PE
    Gynecol Oncol; 2005 Sep; 98(3):353-9. PubMed ID: 16005947
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uterine papillary serous carcinoma: patterns of failure and survival.
    Wang W; DO V; Hogg R; Wain G; Brand A; Bull C; Stenlake A; Gebski V
    Aust N Z J Obstet Gynaecol; 2009 Aug; 49(4):419-25. PubMed ID: 19694700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Uterine sarcomas: clinical and histopathological aspects. Report on 15 cases].
    Leung F; Terzibachian JJ; Aouar Z; Govyadovskiy A; Lassabe C
    Gynecol Obstet Fertil; 2008 Jun; 36(6):628-35. PubMed ID: 18538624
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Limitations of adjuvant radiotherapy for uterine sarcomas spread beyond the uterus.
    Dusenbery KE; Potish RA; Judson P
    Gynecol Oncol; 2004 Jul; 94(1):191-6. PubMed ID: 15262141
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of optimal debulking in advanced stage serous carcinoma of the uterus.
    Moller KA; Gehrig PA; Van Le L; Secord AA; Schorge J
    Gynecol Oncol; 2004 Jul; 94(1):170-4. PubMed ID: 15262137
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment results of tonsillar lymphoma: a 10-year experience.
    Mohammadianpanah M; Omidvai S; Mosalei A; Ahmadloo N
    Ann Hematol; 2005 Apr; 84(4):223-6. PubMed ID: 15042316
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.